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When analysing and reporting data from long-term drug trials in bipolar disorder, it has become the standard to
break down the outcome into the prevention of mania and the prevention of depression. However, as illustrated
by a theoretical example, this approach may confer a potential analysis bias. The point is that when mania or
depression, whatever appears first, is considered an endpoint, then an endpoint of mania will exclude an endpoint
of depression and vice versa. The risk of such bias is reduced when the time course is taken into consideration in
the analysis.
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Breaking down the analysis by polarity of relapses
When analysing and reporting data from long-term
drug trials in bipolar disorder, it has become the stand-
ard to break down the outcome into the prevention of
treatment-emergent mania and the prevention of
treatment-emergent depression. Even such separation
is usually a secondary outcome/analysis which the tri-
als are not powered for, it plays a significant role in the
interpretation of trial results, e.g. when they are quali-
tatively translated into guideline recommendations
(Grunze et al. 2013) or quantitatively translated into a
so-called polarity index (Popovic et al. 2012). The first
studies where this approach revealed significant differ-
ential drug efficacies were the two pivotal studies test-
ing lamotrigine against placebo, including lithium as a
third arm to test the assay sensitivity (Bowden et al.
2003; Calabrese et al. 2003). In both studies, applying
survival analysis, lamotrigine did better than placebo
in terms of preventing new episodes of depression but
not mania, whereas lithium prevented mania but not
depression as compared to the placebo. These studies* Correspondence: rasmus.licht@rn.dk
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reproduction in any medium, provided the origwere major sources in a metanalysis by Geddes et al.
(2004) addressing the preventive efficacy of lithium
based on categorical data, and again, lithium did not
do better than placebo in the prevention of depression.
This result had a major impact on the understanding
of lithium until recently when Weisler et al. (2011) in a
pivotal trial on quetiapine clearly demonstrated that
lithium did prevent depression better than placebo.
The breakdown-by-polarity strategy of analysis, to our
knowledge, has never been questioned in the literature,
although it may lead to distorted results (analysis bias).
The simple point to be made here is that when mania or
depression, whatever appears first, is considered an end-
point, then an endpoint of mania will exclude an end-
point of depression and vice versa. This implicates that
if a drug, for example, reduces the risk of mania but not
depression in comparison to placebo, then this drug will
actually do worse than placebo in preventing depression,
because more patients will then reach an endpoint of
mania in the placebo group than in the drug group and
thereby not have the chance to develop depression fol-
lowing mania.A theoretical example
Take the following theoretical extreme example: A group
of 100 untreated patients with bipolar disorder areis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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episodes. Of these, 40 patients relapse into mania after
the first 0.5 year and subsequently into depression
after 1.5 years, and 40 patients relapse into depression
after the first 0.5 year and subsequently into mania
after 1.5 years; the remaining 20 patients stay euthymic
during the 2 years. Instead, we now assume that the
100 patients had been randomised into treatment with
drug A, reducing the risk of mania with 50% at 0.5 year
but with no influence on depression or to placebo with
no preventive efficacy, and that the patients had been
followed over the same specific 2 years period of time.
In the drug group 10 patients would then have an end-
point of mania and 30 patients an endpoint of depres-
sion, whereas in the placebo group 20 patients would
have an endpoint of mania and 20 patients would have
an endpoint of depression. Therefore, the risks of
reaching endpoints of mania and of depression with
drug A were respectively 0.2 and 0.6 and with placebo
0.4 and 0.4, i.e. the relative risk of reaching an endpoint
of depression with drug A versus placebo is 1.5. Look-
ing at any episode as outcome, a risk of 0.8 is found in
both groups.
Now moving on from the simple analysis of relative
risk based on a categorical outcome measure to a
Kaplan-Meier survival analysis, the probability of stay-
ing euthymic will be 0.4 after 0.5 year and 0.2 (0.4 ×
0.5) after 1.5 years in the drug group and 0.2 after
0.5 year in the placebo group. The probability of not
relapsing into mania (with relapses into depression
censored at 0.5 year) will be 0.8 after 0.5 year and
throughout in the drug group and 0.6 after 0.5 year
and throughout in the placebo group. The probability
of not relapsing into depression (with relapses into
mania censored at 0.5 year) will be 0.6 after 0.5 year
and 0.3 (0.6 × 0.5) after 1.5 year in the drug group, and
0.6 after 0.5 years and throughout in the placebo
group. Here it is assumed that the only censoring tak-
ing place is that due to endpoint of the opposite polar-
ity. Thus, there is a superior probability of staying
euthymic and of not relapsing into mania in the drug
group, but an inferior probability of not relapsing into
depression over the 2-year study period.
Our example illustrates that not only simple analyses
on categorical data in terms of computing relative risks,
but also Kaplan-Meier survival analyses, may confer a
potential bias when the analysis is broken down by po-
larity of relapse. However, the magnitude of bias is
smallest with the latter approach, where the time
course is taken into account, e.g. by recognising that de-
pression after all appears relatively late in those patients
who were protected from mania by the drug. Other ana-
lytical approaches like the person-year method or the Cox
regression analysis will not overcome the potential biasoutlined here. No matter the approach, the argument
simply relies on the trivial observation that in some
cases of bipolar disorder, the natural course of illness is
characterised by one pole followed by the opposite pole,
or vice versa (Goodwin and Jamison 1990).
Discussion and conclusions
It can be argued that the potential bias in analysis dis-
cussed above is of minor importance under ordinary
study conditions, but unfortunately, the magnitude of
this bias can never be estimated empirically in real trial
samples since such an estimate will require information
on the clinical course of illness during the entire study
period, i.e. beyond potential study endpoints under
maintained/unchanged treatment conditions (placebo
and/or active comparator(s)). It can also be argued that
this potential bias has an only minor impact when a
drug is reducing the risk of both poles equally. However,
when a drug demonstrates better preventive efficacy on
one pole than on the other, then it should be born in
mind that such a differential efficacy may be overesti-
mated for the reason given here, and we would warn
against attempting to quantify such a differential effi-
cacy. We would advocate for approaches that take the
time course into consideration.
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